8-K ·Filed Apr 6, 2026
8-K Item 2.02: Earnings release
Actionable Insight • Neutral
Monitor Biogen's upcoming full earnings release for confirmation of the $34 million charge and any additional financial details. The preliminary nature of this filing means final results could differ.
Final — all horizons settled through T+60d
BIIB ▲ +21.77% at T+60d
NEUTRAL call ✓ call won +21.77% · α vs SPY +8.59% · entry $172.25 → $209.74
T+1d
+1.95%
call +1.95% · α +1.89%
$175.61
settled 6mo ago
T+5d
+2.03%
call +2.03% · α -2.11%
$175.74
settled 6mo ago
T+20d
+8.33%
call +8.33% · α -0.65%
$186.60
settled 5mo ago
T+60d
+21.77%
call +21.77% · α +8.59%
$209.74
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Biogen issued a preliminary earnings update for Q1 2026, expecting a $34 million charge for acquired in-process R&D and milestone expenses, impacting EPS by approximately $0.19 per share. This is a forward-looking estimate ahead of final results.
Key Facts
- Biogen expects a $34 million pre-tax charge for acquired in-process R&D, upfront, and milestone expenses in Q1 2026.
- The charge is expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
- Final results for Q1 2026 are not yet finalized and remain subject to closing procedures.
Financial Impact
Approximately $34 million pre-tax charge, reducing EPS by $0.19 per share
epsdiluted_eps
Risk Factors
- Final financial results may differ from these preliminary estimates.
- The R&D charge could be larger or smaller than expected based on final accounting.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
47% bullish (43 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000875045-26-000039 |
| Document: 0000875045-26-000039-index-headers.html | 0000875045-26-000039 |
| Document: 0000875045-26-000039-index.html | 0000875045-26-000039 |
| Document: 0000875045-26-000039.txt | 0000875045-26-000039 |
| 8-K Data (Synthetic) | 0000875045-26-000039 |
25 reports for BIIB
92% Hit rate best @ T+60▲ +11.76%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
Showing 10 of 25
US Market Status
Market Closed — Opens Mon (65h 5m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access